MTOR and cancer: Activating mutations of proto-oncogenes such as EGFR, PI3K, and AKT as well as inactivating mutations of tumor suppressor PTEN or TSC1/2 causes the activation of the mTOR signaling pathway in a wide range of cancers [11,12].